AMG 510

Phase 2

Amgen

AMG 510 is one of 51 therapeutic programs targeting Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Lung CancerActive, not recruiting

Lung CarcinomaUnknown

Lung CancerPhase 2

Active, not recruiting

Lung CarcinomaPreclinical

Unknown

Competition

Competitive Landscape

686 competitors in Lung Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Preclinical

9 2

Vizimpro

Pfizer

Preclinical

3 3

Libtayo

Regeneron

Preclinical

3 4

Talzenna

Pfizer

Preclinical

2 5

Folvite

Xylocaine

2 7

Immunotherapy

Bristol-Myers Squibb

Preclinical

5 8

AMG 510

Amgen

Phase 2

1 9

Paclitaxel and Carboplatin

Bristol-Myers Squibb

Preclinical

2 10

Rilotumumab

Amgen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Active, not recruiting

Lung Cancer

NCT05118854

Clinical

Trials by Indication[1]

Lung Cancer1 trial

A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05118854·13 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AMG 510. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for AMG 510. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Amgen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: Amgen

AMG 510

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News